Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
Conclusion: Disease progression was associated with significant increases in HCRU and costs. Delays in progression were associated with lower cumulative healthcare costs. Earlier use of more clinically effective treatments to delay progression may reduce the economic burden among these patients.PMID:38647165 | DOI:10.57264/cer-2023-0166
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Authors: Clara Lam Brandon Diessner Katherine Andrade Sydnie Stackland Leah Park Sandhya Mehta Feng Lin Winghan Jackie Kwong Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Emergency Medicine | General Medicine | Healthcare Costs | HER2 | Insurance | Medicare | Study